Objectives
==========

This study evaluates modulation of rheumatoid arthritis (RA) synovial apoptosis by therapy with the soluble tumor necrosis factor (TNF) alpha receptor (etanercept).

Methods
=======

Apoptosis (TUNEL \[transferase-mediated UTP end labeling\] combined with morphology), cell-surface markers (CD3, CD68, CD163, Fas), FLIP and granzyme B were evaluated by immunohistochemistry in synovial biopsies from 12 RA patients before and after 8 weeks of treatment with etanercept. Moreover, the *in vitro* effect of etanercept on FLIP expression and on the death of mononuclear cells (MNCs) derived from synovial fluid (SF) was determined in five RA patients by flow cytometry.

Results
=======

Etanercept treatment increased synovial apoptosis and decreased the number of CD68-positive and CD163-positive monocyte/macrophages and FLIP expression (*P* \< 0.05). No significant changes were observed for the expression of CD3, Fas and granzyme B. *In vitro*, low concentrations of etanercept (1 and 10 μg/ml) increased cell death (*P* \< 0.05) in the SF CD14-positive monocyte/macrophage population after 24 hours\' incubation, while higher concentrations (100 μg/ml) had no effect. FLIP expression in this population did not change after *in vitro* culture with either low or high doses. The *in vitro* culture with etanercept did not induce any changes in FLIP expression or apoptosis level in SF CD3-positive cells.

Conclusion
==========

Therapy with etanercept at clinically relevant concentrations increased RA synovial monocyte/macrophage apoptosis, suggesting an alternate pathway to explain the decrease in synovial cellularity observed after anti-TNF therapy.
